Sociodemographic characteristics and cardiovascular, stroke and bleeding risk factors
| No antithrombotic treatment | VKA | Antiplatelet agents | VKA + antiplatelet | Dabigatran | |
|---|---|---|---|---|---|
| n=22 585 | 5724 | 9057 | 7424 | 227 | 153 |
| Gender | |||||
| Female (%) | 46.9 | 48.3 | 50.3 | 36.6 | 38.6 |
| Male (%) | 53.1 | 51.7 | 49.7 | 63.4 | 61.4 |
| Age (years; mean, SD) | 69.6 (16.4) | 73.4 (10.3) | 74.6 (12.9) | 72.4 (9.9) | 71.4 (11.0) |
| >75 years (%) | 45.5 | 51.1 | 53.6 | 43.6 | 39.2 |
| MEDEA23 (mean, SD) | 0.44 (0.92) | 0.52 (0.90) | 0.50 (0.91) | 0.51 (0.82) | 0.29 (0.97) |
| ≥4th quintile (%) | 36.6 | 39.4 | 39.1 | 41.0 | 29.9 |
| BMI (kg/m2; mean, SD) | 28.6 (5.1) | 30.2 (5.3) | 29.2 (5.2) | 30.1 (5.5) | 29.5 (4.4) |
| BMI ≥30: obesity (%) | 34.7 | 46.8 | 38.8 | 44.4 | 40.2 |
| Missing values (%) | 46.4 | 25.3 | 33.9 | 25.6 | 39.9 |
| Smoking status (%) | |||||
| Non-smoker | 65.7 | 70.0 | 70.3 | 62.8 | 66.2 |
| Current smoker | 16.9 | 10.3 | 11.8 | 12.2 | 9.6 |
| Ex-smoker | 17.4 | 19.7 | 17.9 | 25.0 | 24.2 |
| Missing values | 30.9 | 19.5 | 18.4 | 17.2 | 11.1 |
| Alcohol intake (%) | |||||
| Non-consumer | 71.8 | 70.3 | 70.4 | 67.5 | 63.3 |
| Mild-moderate | 25.7 | 27.3 | 27.2 | 31.3 | 32.7 |
| Alcohol abuse | 2.5 | 2.4 | 2.4 | 1.2 | 4.1 |
| Missing values | 49.0 | 29.0 | 35.2 | 26.9 | 35.9 |
| CHADS2 score7 (%) | |||||
| 0 | 31.7 | 15.3 | 19.9 | 11.9 | 18.3 |
| 1 | 29.6 | 31.9 | 32.6 | 31.3 | 38.6 |
| 2 | 24.8 | 34.8 | 30.6 | 27.8 | 26.1 |
| ≥3 | 14.0 | 18.0 | 16.9 | 29.1 | 17.0 |
| CHA2DS2VASc score25 (%) | |||||
| 0–1 | 34.5 | 17.8 | 22.3 | 13.6 | 24.2 |
| 2 | 16.5 | 19.5 | 19.2 | 18.5 | 24.8 |
| 3 | 21.4 | 26.6 | 23.8 | 26.4 | 20.3 |
| ≥4 | 27.6 | 36.0 | 34.7 | 41.3 | 36.8 |
| HAS-BLED score10 11 (%) | |||||
| 0 | 16.3 | 6.6 | 0.0 | 0.0 | 4.1 |
| 1–2 | 63.6 | 68.9 | 42.5 | 34.3 | 81.6 |
| ≥3 | 20.2 | 24.4 | 57.4 | 65.7 | 14.3 |
BMI, body mass index; VKA, vitamin K antagonists.